scholarly journals The impact of type II diabetes mellitus in patients with autosomal dominant polycystic kidney disease

2011 ◽  
Vol 27 (7) ◽  
pp. 2862-2865 ◽  
Author(s):  
Berenice Reed ◽  
Imed Helal ◽  
Kim McFann ◽  
Wei Wang ◽  
Xiang-Dong Yan ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Kidney Disease ◽  
Polycystic Kidney Disease ◽  
Type Ii Diabetes ◽  
Autosomal Dominant ◽  
Type Ii Diabetes Mellitus ◽  
Type Ii ◽  
Polycystic Kidney ◽  
Autosomal Dominant Polycystic Kidney ◽  
The Impact

Autosomal Dominant Polycystic Kidney Disease: Clinical Assessment of Rapid Progression

2018 ◽  
Vol 48 (4) ◽  
pp. 308-317 ◽  
Author(s):  
Mónica Furlano ◽  
Irene Loscos ◽  
Teresa Martí ◽  
Gemma Bullich ◽  
Nadia Ayasreh ◽  
...  
Keyword(s):  
Clinical Practice ◽  
Kidney Disease ◽  
Polycystic Kidney Disease ◽  
Autosomal Dominant ◽  
Rapid Progression ◽  
Kidney Volume ◽  
Polycystic Kidney ◽  
Decision Algorithm ◽  
Autosomal Dominant Polycystic Kidney ◽  
The Impact

Background: Autosomal dominant polycystic kidney disease (ADPKD) causes the development of renal cysts and leads to a decline in renal function. Limited guidance exists in clinical practice on the use of tolvaptan. A decision algorithm from the European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) Working Groups of Inherited Kidney Disorders and European Renal Best Practice (WGIKD/ERBP) has been proposed to identify candidates for tolvaptan treatment; however, this algorithm has not been assessed in clinical practice. Methods: Eighteen-month cross-sectional, unicenter, observational study assessing 305 consecutive ADPKD patients. The ERA-EDTA WGIKD/ERBP algorithm with a stepwise approach was used to assess rapid progression (RP). Subsequently, expanded criteria based on the REPRISE trial were applied to evaluate the ­impact of extended age (≤55 years) and estimated glomerular filtration rate (eGFR; ≥25 mL/min/1.73 m2). Results: Historical eGFR decline, indicative of RP, was fulfilled in 26% of 73 patients who were candidates for RP assessment, mostly aged 31–55 years. Further tests including ultrasound and MRI measurements of kidney volume plus genetic testing enabled the evaluation of the remaining patients. Overall, 15.7% of patients met the criteria for rapid or likely RP using the algorithm, and the percentage increased to 27% when extending age and eGFR. Conclusions: The ERA-EDTA WGIKD/ERBP algorithm provides a valuable means of identifying in routine clinical practice patients who may be eligible for treatment with tolvaptan. The impact of a new threshold for age and eGFR may increase the percentage of patients to be treated.

Prevalence of nephrolithiasis in polycystic kidney disease

Open Medicine ◽  
2011 ◽  
Vol 6 (4) ◽  
pp. 497-501
Author(s):  
Alma Idrizi ◽  
Myftar Barbullushi ◽  
Margarita Gjata ◽  
Alketa Koroshi ◽  
Enver Roshi ◽  
...  
Keyword(s):  
Kidney Disease ◽  
Polycystic Kidney Disease ◽  
Autosomal Dominant ◽  
Stone Formation ◽  
Polycystic Kidney ◽  
Metabolic Factors ◽  
Survival Curves ◽  
Autosomal Dominant Polycystic Kidney ◽  
Tract Infections ◽  
The Impact

AbstractWe aim to define the prevalence of nephrolithiasis, the impact of anatomic and metabolic factors to stone formation and prognosis of patients with autosomal dominant polycystic kidney disease in Albania. We included 200 patients with autosomal dominant polycystic kidney from 2002 to 2009. The patients underwent X-ray, renal ultrasonography. We performed the metabolic evaluation of blood and urine. Survival times were calculated as the time to dialysis, transplantation, or death. Kaplan-Meier product-limit survival curves were constructed. Log rank test was used to compare the survival curves. Nephrolithiasis was present in 116 of our patients with autosomal dominant polycystic kidney disease (58%), with a mean age 46.4±5.7 years. Sixty five patients with kidney stones (56%) were women. The stones were composed primarily of urate (47%) and calcium oxalate (39%), and other compounds 14%. In 40% of patients the presence of stones was associated with a history of urinary tract infections and flank pain. In our study the prevalence of nephrolithiasis is 58%, higher than it reported in literature. Except anatomic and metabolic factors, there are other contributor factors to stone formation in our patients such socioeconomic status of patients, geographic zones and dietary habits.

Autosomal Dominant Polycystic Kidney Disease Reduces the Risk of Diabetes Mellitus

2006 ◽  
Vol 37 (3) ◽  
pp. 360-364 ◽  
Author(s):  
Maria Pietrzak-Nowacka ◽  
Jacek Rózanski ◽  
Krzysztof Safranow ◽  
Karolina Kedzierska ◽  
Grazyna Dutkiewicz ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Kidney Disease ◽  
Polycystic Kidney Disease ◽  
Autosomal Dominant ◽  
Polycystic Kidney ◽  
Autosomal Dominant Polycystic Kidney

Cardiovascular risk and quality of life in autosomal dominant polycystic kidney disease patients in therapy with tolvaptan: A pilot study

2020 ◽  
Vol 18 ◽  
Author(s):  
Silvia Lai ◽  
Marco Mangiulli ◽  
Adolfo M Perrotta ◽  
Antonietta Gigante ◽  
Ludovica Napoleoni ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Kidney Disease ◽  
Polycystic Kidney Disease ◽  
Autosomal Dominant ◽  
Clinical Laboratory ◽  
Intima Media Thickness ◽  
Polycystic Kidney ◽  
Autosomal Dominant Polycystic Kidney ◽  
The Impact

Introduction: ardiovascular (CV) complications are the most frequent cause of morbidity and mortality in autosomal dominant polycystic kidney disease (ADPKD) patients. In 2017, the Italian Medicines Agency authorised tolvaptan, a vasopressin V2 receptor antagonist, for the treatment of ADPKD, based on the Tolvaptan Phase 3 Efficacy and Safety Study in ADPKD (TEMPO 3: 4), TEMPO 4: 4 and Replicating Evidence of Preserved Renal Function: An Investigation of Tolvaptan Safety and Efficacy (REPRISE) studies. Aim of the study: To assess the impact of tolvaptan on CV risk and quality of life, evaluated by nutritional, inflammatory, metabolic, instrumental parameters and psychocognitive tests in ADPKD patients. Methods and Materials: We evaluated 36 patients with ADPKD; 10 patients (7 males, mean age 42.5±7.0 years) treated with tolvaptan and 26 controls (11 males, mean age 36.7±9.1 years). They underwent, at T0, monthly, and at T1 (1 year) clinical, laboratory and instrumental evaluation, in addition to psychocognitive tests. Results: In ADPKD patients treated with tolvaptan we found at T1 a decrease in carotid intima media thickness (p=0.048), epicardial adipose tissue thickness (p=0.002), C-reactive protein (p=0.026), sympathovagal balance during the night (p=0.045) and increases flow mediated dilation (p=0.023) with a reduction in depression (Hamilton and Beck tests, p=0.008 and p=0.002, respectively) compared with controls. Conclusions: These preliminary results suggest that treatment with tolvaptan could improve early atherosclerosis and endothelial dysfunction markers and improve the mood in ADPKD patients (probably by the acting on endothelial cell and adipocyte V2 receptors).

Sign in / Sign up

Export Citation Format

Share Document